Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
· biomea fusion, inc.
AI Briefing
- Biomea Fusion announces positive 52-week results from Phase II COVALENT-111 study in type 2 diabetes.
- The study evaluated the efficacy, safety, and tolerability of icovamenib in patients with T2D.
- Results were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes in Barcelona.
Advertisement